Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2022

View Archived Issues

Immune suppressive glycoprotein-targeting MAb reported

CAP2 is increased in patients with AD and correlates with tau pathology

PP2B inhibition clears tau toxicity in experimental AD

Amyloid beta 42 impacts the expression of SPPL2B in AD

Anc80L65 vector combined with new surgical technique for hearing loss gene therapy

OLX-07010 shows promising efficacy in mouse models of tauopathy

TREM2 agonistic MAb attenuates tau burden and neurodegeneration

Researchers develop new murine model of AD

Sorrento reports findings with universal chimeric mRNA based COVID-19 vaccine

ALS Therapy Development Institute patents new compounds for ALS

Merck & Co. synthesizes new anti-HIV compounds

MagicMed Industries presents 5-HT2A receptor agonists

Incyte divulges new JAK2 inhibitors

Vertex Pharmaceuticals synthesizes new APOL1 inhibitors

Volastra collaborates with Bristol Myers Squibb to discover and develop oncology drug candidates

Grant supports Neuromagen's development of AGS-499 for ALS

Ixaka expands IP portfolio to allow use of TNP gene delivery platform across multiple areas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...